News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Pentagon will escort all journalists, close the Correspondents' Corridor, and move the press workspace off the main Pentagon building while appealing.
  • White House is assessing Iran parliament speaker Ghalibaf for negotiated talks amid a five-day pause in strikes to protect global oil markets.
  • About $580 million of Brent and WTI futures traded minutes before Trump's Iran post, markets spiked, and Iran's parliament denied any talks.
  • Kim Jong Un declared North Korea's nuclear status irreversible and approved a five-year plan raising defense spending to 15.8%.
  • Gilead agreed to acquire Ouro Medicines for $1.675 billion plus up to $500 million in milestones, with Galapagos sharing development costs.
  • Analysts recommend a long on Micron, citing sold-out HBM capacity and a $550 target over 180 trading days.
  • Berkshire is pitched as a buy after CEO Greg Abel's $15 million stock purchase and the restart of share repurchases.

Latest Articles

BofA Cuts Teladoc Price Target to $7, Cites Mixed Segment Outlook

BofA Cuts Teladoc Price Target to $7, Cites Mixed Segment Outlook

BofA Securities reduced its target on Teladoc Health to $7 from $7.50 while keeping a Neutral rating, citing continued uncertainty in the company’s BetterHelp and Chronic Care segments. The firm lowered its valuation multiple to 4.1x calendar year 2026 EBITDA and noted flat sequential BetterHelp user growth alongside weaker year-over-year trends. T…

Golden Dome Missile Shield Hits First Anniversary With Limited Visible Progress

Golden Dome Missile Shield Hits First Anniversary With Limited Visible Progress

One year after the executive order creating the Golden Dome missile-defense initiative, the program has spent little of the $25 billion appropriated and remains stalled while officials and industry stakeholders debate classified elements of its space-based architecture. Small prototype contracts have been awarded, but major procurement and broad fu…

Canada’s IPO pipeline looks set to reopen in 2026 as market sentiment improves

Canada’s IPO pipeline looks set to reopen in 2026 as market sentiment improves

After roughly four years of subdued initial public offering activity, Canada’s primary equity market is showing signs of revival for 2026. Market participants say high interest rates and inflation, regulatory friction, and other headwinds kept many firms out of the public markets, but recent equity market strength and a sizable October deal have en…

Pfizer at $26 Looks Like a Setup, Not a Surrender

Pfizer at $26 Looks Like a Setup, Not a Surrender

Pfizer is trading around $25.88 with improving momentum and a 6.65% dividend yield. Even as the market debates big-picture healthcare policy shifts, PFE’s valuation looks compressed versus its cash generation profile and the stock is building a base just under the 52-week high. This trade idea targets a measured breakout with defined risk, leaning …

TD Cowen Starts Coverage on Zimmer Biomet, Assigns Buy and $109 Target

TD Cowen Starts Coverage on Zimmer Biomet, Assigns Buy and $109 Target

TD Cowen has initiated coverage of Zimmer Biomet (NYSE: ZBH) with a Buy rating and a $109 price target, implying about 25% upside from the current share price of $87.32. The firm points to a stronger growth and profitability outlook, underpinned by a 71.6% gross profit margin and 5.5% revenue growth over the past 12 months, while noting prior execu…

TD Cowen Starts Coverage of Beta Bionics With Hold, Cites Modest Upside

TD Cowen Starts Coverage of Beta Bionics With Hold, Cites Modest Upside

TD Cowen initiated coverage of Beta Bionics (NASDAQ:BBNX) with a Hold rating and a $17.00 price target, noting solid early commercial traction for the iLet system but expressing concerns that projected revenue gains may not justify an outsized valuation. The firm highlighted strong recent top-line growth alongside signs of a potential slowdown in n…

TD Cowen Initiates Coverage of Stryker With Hold Rating, $387 Price Target

TD Cowen Initiates Coverage of Stryker With Hold Rating, $387 Price Target

TD Cowen began coverage of Stryker Corporation (NYSE: SYK) with a Hold rating and a $387 price target shortly before the company's upcoming earnings report. The firm praised Stryker's long run of organic growth and renewed focus on margins, while noting valuation metrics that present both potential upside and premium multiples. Recent corporate mov…

J.P. Morgan Flags Legrand as Near-Term Positive Catalyst Ahead of Q4 Results

J.P. Morgan Flags Legrand as Near-Term Positive Catalyst Ahead of Q4 Results

J.P. Morgan has put Legrand on a positive catalyst watch ahead of the group's fourth-quarter results due Feb. 12, reiterating an overweight rating and a €165 price target. The bank highlights upside versus consensus for the quarter, the company's exposure to robust data-center demand, a valuation discount relative to peers, and elevated short inter…

Fugro and Fraunhofer Finish Geophysical Survey for German North Sea Site

Fugro and Fraunhofer Finish Geophysical Survey for German North Sea Site

Fugro and Fraunhofer IWES have completed a geophysical site characterization in the German North Sea for the Federal Maritime and Hydrographic Agency (BSH). The April-May survey combined sub-bottom profiler and ultra-high-resolution multichannel seismic data to map seabed and sub-seabed structures, yielding a preliminary interpretation intended to …

Jefferies Sticks with Hold on Pinterest Ahead of February Earnings, Sees Limited Near-Term Catalysts

Jefferies Sticks with Hold on Pinterest Ahead of February Earnings, Sees Limited Near-Term Catalysts

Jefferies has reaffirmed a Hold rating and a $28.00 price target on Pinterest Inc (NYSE: PINS) ahead of the company’s earnings report on February 12. While acknowledging seasonally reasonable revenue plans and a resilient holiday ad market, the firm warned that Pinterest’s fiscal 2026 EBITDA margin assumptions may be vulnerable to downward revision…